AstraZeneca is a large pharma headquartered in UK. Over the past three years, AstraZeneca has been involved in 39 licensing and acquisition transactions, with a primary focus on Small Molecules (16 deals). The company currently has 50 active clinical trials, primarily in Oncology.
Deals (12mo)
11
Active Trials
50
Top Modality
Small Molecules
Focus Area
Oncology
Licensing, acquisition, and partnership transactions involving AstraZeneca in the past 12 months.
| Asset |
|---|
| Partner |
|---|
| Modality |
|---|
| Phase |
|---|
| Type |
|---|
| Date |
|---|
| EGFR degrader | Pinetree Therapeutics | Small Molecules | Unknown | acquisition | Apr 2026 |
| JAB-23E73 | Jacobio Pharmaceuticals | Small Molecules | Unknown | license | Apr 2026 |
| EGFR degrader | Pinetree | Small Molecules | Unknown | license | Apr 2026 |
| Enhertu (trastuzumab deruxtecan) | Daiichi Sankyo | ADC | Approved | collaboration | Apr 2026 |
| JAB-23E73 | Jacobio Pharmaceuticals | Small Molecules | Unknown | license | Apr 2026 |
| EGFR degrader | Pinetree | Small Molecules | Unknown | license | Apr 2026 |
| AZP-3813 | Amolyt Pharma | Peptides | Unknown | acquisition | Apr 2026 |
| SYH2082 | CSPC Pharmaceutical | Peptides | Preclinical | license | Jan 2026 |
| SYH2083 | CSPC | Peptides | Unknown | license | Jan 2026 |
| Anti-BRAF V600E-001 | Karyopharm Therapeutics | ADC | Phase 2 | collaboration | Nov 2025 |
Showing 10 of 13 recent transactions. Upgrade to Pro for full deal history with financials.
Therapeutic areas and modalities where AstraZeneca is most active based on deal history and clinical trial data.
Key indicators of AstraZeneca's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Acquisition Appetite
Strategic Priorities
AstraZeneca has 50 active clinical trials across 6 development phases.
20
Unknown
5
Phase 4
1
Not Applicable
12
Phase 1
9
Phase 2
3
Phase 3
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Peptides Benchmarks
Upfront, milestone, and royalty benchmarks for peptides deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
AstraZeneca is a large pharma company based in UK that has been actively engaged in licensing transactions across the biopharma landscape. With 39 deals over the past three years, AstraZeneca ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for AstraZeneca include Oncology (18 deals and trials), Solid Tumors (14 deals and trials), Mega Deals (12 deals and trials), and Autoimmune (12 deals and trials). In terms of modality, AstraZeneca has shown particular interest in small molecules, peptides, car-t.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for AstraZeneca and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against AstraZeneca's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.
© 2026 Ambrosia Ventures. All rights reserved.
Benchmarks powered by 1,900+ real biopharma licensing deals